Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
Public ClinicalTrials.gov record NCT01772368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Six-Period Crossover, Dose-Ranging Study to Evaluate the Efficacy and Safety of Four Doses of FS Spiromax (Fluticasone Propionate/Salmeterol Xinafoate Inhalation Powder) Administered as Single Doses Compared With Single Doses of Fluticasone Propionate Spiromax and Open Label Advair Diskus in Adult and Adolescent Subjects With Persistent Asthma
Study identification
- NCT ID
- NCT01772368
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- Fp MDPI Drug
- FS MDPI Drug
- Advair Diskus Drug
- Albuterol Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2012
- Primary completion
- May 31, 2013
- Completion
- May 31, 2013
- Last update posted
- Jun 11, 2017
2013
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 10453 | Denver | Colorado | — | — |
| Teva Investigational Site 10452 | North Dartmouth | Massachusetts | — | — |
| Teva Investigational Site 10455 | St Louis | Missouri | — | — |
| Teva Investigational Site 10454 | Skillman | New Jersey | — | — |
| Teva Investigational Site 10448 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 10451 | Medford | Oregon | — | — |
| Teva Investigational Site 10449 | Portland | Oregon | — | — |
| Teva Investigational Site 10457 | El Paso | Texas | — | — |
| Teva Investigational Site 10450 | New Braunfels | Texas | — | — |
| Teva Investigational Site 10456 | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01772368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01772368 live on ClinicalTrials.gov.